BALAXI

Balaxi Pharmaceuticals Balance Sheet

₹22.84+0.75%
Market cap
₹126 crore
P/E
52.0
P/B
0.51
ROE
0.6%
Dividend yield
1.20%

As of Mar 2022, Balaxi Pharmaceuticals had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 8,915.78% from Mar 2023.

Balaxi Pharmaceuticals balance sheet

As at each financial year end, newest first. H1 = half-year.

Balaxi Pharmaceuticals balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50010.1810.911.0411.04
Reserves8,500143136163181
Borrowings1,20013.3119.453.4357.65
Other liabilities3,50043.4837.5825.1830.3
Total liabilities13,700240258310337
Fixed assets6,50018.1116.3135.6548.36
Capital work in progress400100100100100
Investments2,50047.9351.6762.0767.41
Other assets4,30071.977.593.1101
Total assets13,700240258310337

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Balaxi Pharmaceuticals balance sheet — frequently asked questions

What is the total debt of Balaxi Pharmaceuticals?

Balaxi Pharmaceuticals reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹13.31 crore as of Mar 2023.

What is Balaxi Pharmaceuticals' debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Balaxi Pharmaceuticals' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Balaxi Pharmaceuticals' total assets?

Balaxi Pharmaceuticals' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Balaxi Pharmaceuticals With ATS

Track BALAXI live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.